Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02536404 · ClinicalTrials.gov registry record · Phase 2
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
A Phase 2 study, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT02536404 is a Phase 2 study that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 118 participants.
The verdict
NCT02536404, a Phase 2 study, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.
Interventions
- DRUG Placebo
- DRUG Etrasimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2016-01-25 |
| Est. Completion | 2018-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02536404
The ClinicalTrials.gov registry entry for NCT02536404 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arena Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02536404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02536404 about?
NCT02536404 is a clinical study titled "Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis". The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.
What is the current status of trial NCT02536404?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2016-01-25. Estimated completion is 2018-11-01.
What interventions are being tested in trial NCT02536404?
The interventions under investigation include: Placebo (DRUG), Etrasimod (DRUG).
Who is sponsoring clinical trial NCT02536404?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.